Addyi Max Dose: Flibanserin Titration, Ceiling, and What Comes Next

What Is the Maximum Dose of Addyi?

The FDA-approved maximum dose of flibanserin is 100 mg once daily at bedtime. The FDA label specifies no lower starting dose and no upward titration pathway, 100 mg at bedtime is the single approved regimen for all adult premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). Prescribers sometimes ask whether a 50 mg starting dose makes sense for tolerability. The pharmacokinetic data do not support it as a formal step.

Why There Is No Dose Above 100 mg

Flibanserin's dose-response curve flattens at 100 mg for efficacy while CNS adverse effects, particularly somnolence, dizziness, and hypotension, continue to increase with higher exposures. The phase 2 dose-finding studies evaluated 25 mg twice daily, 50 mg twice daily, and 100 mg at bedtime before settling on the bedtime regimen. Those early pharmacodynamic data showed that shifting the dose to bedtime reduced daytime somnolence without sacrificing the receptor occupancy needed for efficacy. Doubling to 200 mg was never formally tested in phase 3 because the safety signal at higher exposures was prohibitive.

The REMS Constraint on Prescribing

Addyi is available only through the Addyi REMS program. The FDA REMS page requires certified prescribers, certified pharmacies, and patient enrollment. No off-label dose escalation pathway exists within REMS-compliant prescribing. This regulatory structure means that any attempt to prescribe above 100 mg falls outside the program's approved parameters entirely.

How Flibanserin Works: Mechanism Behind the Single-Dose Strategy

Flibanserin acts as a postsynaptic serotonin 1A (5-HT1A) agonist and serotonin 2A (5-HT2A) antagonist, with weaker dopamine D4 antagonism. Preclinical and early clinical pharmacology data support the model that this receptor profile shifts the balance between inhibitory serotonergic tone and excitatory dopaminergic and noradrenergic activity in the medial prefrontal cortex, a region tied to sexual motivation. The mechanism is distinct from phosphodiesterase inhibitors or hormonal therapies.

Why Bedtime Dosing Shapes the Entire Regimen

Giving 100 mg at bedtime rather than in the morning substantially reduces somnolence and dizziness during waking hours. A crossover pharmacokinetic study referenced in the FDA label found that peak plasma concentration (Cmax) of approximately 0.35 mcg/mL occurs roughly 45 to 75 minutes post-dose. The FDA's clinical pharmacology review documents a half-life of 11 hours, meaning residual plasma levels persist into the next morning, which is why the alcohol and CNS depressant warnings extend through the following day.

Receptor Kinetics and the Ceiling Effect

Because 5-HT1A and 5-HT2A receptors approach saturation near the 100 mg dose range, the benefit-risk ratio deteriorates sharply above this exposure. Published receptor-binding data confirm that no additional receptor agonism or antagonism is gained by doubling the dose, while sedative adverse effects scale with plasma exposure rather than with receptor selectivity. Clinicians should understand this is a pharmacological ceiling, not an arbitrary regulatory number.

Evidence from Phase 3 Trials: What 100 mg Actually Delivers

The phase 3 program for flibanserin comprised five trials: DAISY, VIOLET, BEGONIA, SNOWDROP, and MAGNOLIA. These studies collectively enrolled more than 5,000 premenopausal women. The primary endpoints were change from baseline in the number of satisfying sexual events (SSEs) per 28 days and change in the Female Sexual Distress Scale-Revised (FSDS-R) desire domain score.

BEGONIA Trial Results

BEGONIA (N=1,378) is the most frequently cited efficacy trial. Published in the Journal of Sexual Medicine in 2014, it randomized premenopausal women with HSDD 1:1 to flibanserin 100 mg at bedtime or placebo for 24 weeks. Flibanserin produced a mean increase of 1.0 SSE per 28 days versus 0.4 in the placebo group (P<0.001). The FSDS-R desire domain score improved by 19.0 points in the flibanserin group compared with 14.2 points for placebo (P<0.001). 38% of flibanserin-treated women reported at least a minimally clinically important improvement, compared with 28% for placebo.

VIOLET and DAISY Pooled Context

Across the VIOLET and DAISY trials, which together enrolled approximately 2,400 women, the mean increase in SSEs over placebo ranged from 0.5 to 1.0 per 28-day period. The FDA's statistical review documented effect sizes that were statistically significant but modest in absolute magnitude, a point the agency's advisory committee debated extensively. The clinical relevance of a half-to-one additional SSE monthly is a patient-specific judgment, not a blanket dismissal of the drug's utility.

Adverse Events at the 100 mg Dose

In pooled phase 3 data, the most common adverse effects at 100 mg at bedtime were somnolence (11.4% vs. 3.0% placebo), dizziness (11.2% vs. 2.8%), nausea (10.4% vs. 4.1%), and fatigue (9.2% vs. 5.5%). Syncope occurred in 0.4% of flibanserin-treated patients versus 0.2% on placebo. These rates represent the ceiling-dose profile; no phase 3 data exist for doses above 100 mg because no phase 3 study tested higher amounts.

Does Any Titration Approach Exist in Practice?

The FDA label contains no titration schedule. Some clinicians have informally used a 50 mg starting dose for 1 to 2 weeks in patients with high CNS-sensitivity concerns, then advancing to 100 mg. This is an off-label practice with no published RCT support. The pharmacological rationale is limited, because 50 mg produces sub-therapeutic receptor occupancy and no published data confirm that a 2-week 50 mg run-in reduces adverse events at the full dose.

The 8-Week Minimum Trial Period

The FDA label states that if a patient does not report improvement after 8 weeks at 100 mg at bedtime, the drug should be discontinued. This 8-week threshold is based on the observed time course of receptor adaptation in the phase 3 trials, where statistically significant separation from placebo was detectable at week 4 but clinically meaningful differentiation solidified between weeks 8 and 12. Continuing beyond 8 weeks without any response is not supported by the evidence base.

Real-World Persistence Data

Post-approval real-world data are sobering. A 2018 analysis using IQVIA pharmacy claims data found that median time to discontinuation of flibanserin was approximately 30 days, with only about 25% of patients filling a second prescription. Published adherence research suggests that side effects, cost, and the complexity of the alcohol restriction contribute most to early discontinuation, not lack of efficacy per se. This context matters when counseling patients on realistic expectations.

The Alcohol Interaction: Why It Defines the Dosing Strategy

The alcohol-flibanserin interaction is the most clinically consequential aspect of the drug's risk profile. The FDA's 2015 safety communication warned that concurrent alcohol use produces additive CNS depression, hypotension, and syncope. A dedicated drug-interaction study (N=25) found that the combination of 100 mg flibanserin and two standard alcoholic drinks produced a mean systolic blood pressure drop of 28 mmHg and caused syncope in 4 of 23 evaluable subjects.

CYP3A4 Inhibitors Effectively Create a Higher-Exposure State

Flibanserin is metabolized primarily through CYP3A4 and secondarily through CYP2C19. The FDA label contraindicated all moderate and strong CYP3A4 inhibitors because they produce plasma exposures equivalent to or exceeding what would occur at suprapherapeutic doses. Co-administration with fluconazole 200 mg, for example, increased flibanserin AUC by approximately 7-fold in a dedicated DDI study. This means a CYP3A4 inhibitor in a patient on 100 mg flibanserin is pharmacokinetically similar to giving a much higher dose, and the safety consequences mirror what would be expected from intentional dose escalation.

Weak CYP3A4 Inhibitors and the Gray Zone

Weak CYP3A4 inhibitors such as fluoxetine, ranitidine (where still available), or grapefruit juice are not contraindicated but require clinical caution. The FDA label advises that multiple weak inhibitors taken together may produce a combined effect comparable to a moderate inhibitor. Clinicians reviewing a patient's full medication list before and during flibanserin therapy are applying this drug interaction principle in practice.

When 100 mg Does Not Work: Evidence-Based Next Steps

When a patient has completed a full 8-week trial at 100 mg at bedtime with no meaningful improvement in SSEs or FSDS-R scores, the label-directed response is discontinuation, not dose escalation. The clinical question then becomes: what comes next for a premenopausal woman with persistent HSDD?

Reassessing the HSDD Diagnosis

HSDD is a diagnosis of exclusion. The Endocrine Society's 2019 guidelines on female sexual dysfunction recommend ruling out contributing factors including relationship distress, mood disorders, hypothyroidism, hyperprolactinemia, and inadequate sexual stimulation before attributing lack of response to pharmacological failure. A patient who fails flibanserin may simply have a treatable contributing condition that was not fully characterized at baseline.

Bremelanotide as an Alternative

Bremelanotide (Vyleesi) received FDA approval in June 2019 for the same indication, acquired generalized HSDD in premenopausal women. The FDA label for bremelanotide specifies a 1.75 mg subcutaneous injection taken 45 minutes before anticipated sexual activity, no more than once per 24 hours. Unlike flibanserin, bremelanotide is used on-demand rather than daily, which some patients prefer. The RECONNECT trial (N=1,247) showed a statistically significant increase in SSEs and reduction in distress scores versus placebo at 24 weeks. RECONNECT data are published in Obstetrics and Gynecology.

Testosterone Therapy Off-Label

Testosterone therapy for HSDD in women has a substantial evidence base despite lacking FDA approval for this indication. A 2019 systematic review and meta-analysis by Davis et al., published in The Lancet Diabetes and Endocrinology (N=46 RCTs, 3,176 women), found that transdermal testosterone significantly improved SSEs, desire, arousal, orgasm, and pleasure while reducing sexual distress versus placebo. That meta-analysis is indexed on PubMed. The Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH) both acknowledge the evidence and provide guidance on monitoring. ISSWSH's 2019 consensus on testosterone for women recommends targeting a total testosterone level in the upper quartile of the normal premenopausal reference range, with reassessment at 3 to 6 months.

Psychosexual Therapy as an Adjunct

No pharmacological agent produces durable benefit without addressing psychological and relational contributors. A 2017 Cochrane review on psychological interventions for sexual dysfunction in women found moderate-quality evidence supporting mindfulness-based cognitive therapy and sex therapy in improving desire and distress outcomes. Combining flibanserin with structured psychosexual therapy has not been tested in an RCT, but the mechanistic rationale for additive benefit is sound.

Monitoring Patients on Flibanserin 100 mg

Baseline Assessment

Before initiating flibanserin, a complete medication reconciliation is required to screen for CYP3A4 inhibitors and CNS depressants. Baseline blood pressure should be documented. Formal diagnosis of HSDD using a validated tool such as the FSDS-R or the Decreased Sexual Desire Screener (DSDS) strengthens the clinical record and provides a quantitative baseline for the 8-week reassessment. The DSDS has been validated in peer-reviewed literature.

Follow-Up at 4 and 8 Weeks

The 4-week visit allows early identification of intolerable side effects and reinforcement of the bedtime dosing instruction and alcohol avoidance. The 8-week visit is the decision point specified in the FDA label: continue if meaningful benefit is present, discontinue if not. A structured approach to the 8-week reassessment using the FSDS-R desire domain and a patient-reported SSE diary provides objective data for the continuation decision.

Long-Term Use Considerations

Patients who respond and continue beyond 8 weeks should be reassessed annually for ongoing indication, medication burden review, and any change in relationship or health status that might alter the risk-benefit balance. The long-term safety database from the open-label extension of BEGONIA and VIOLET provides up to 52 weeks of exposure data. Those extension data show no new safety signals emerging beyond week 24, with a stable adverse event profile at 100 mg throughout.

Practical Dosing Summary for Clinicians

Flibanserin's entire approved dosing strategy fits into three sentences. Start at 100 mg at bedtime. Do not exceed 100 mg. Stop at 8 weeks if no response.

The absence of titration reflects the pharmacology, not a gap in the drug's development. Phase 2 tested multiple doses and schedules exhaustively before the bedtime 100 mg regimen emerged as the only configuration where benefits outweighed risks. Prescribers who encounter patients requesting a higher dose or a faster increase should explain that the FDA's clinical review found no efficacy benefit above 100 mg and a substantially worse CNS safety profile, making dose escalation both unapproved and pharmacologically unjustified.

Patients who experience partial benefit at 8 weeks, meaning some improvement in SSEs or distress scores but below their personal threshold, represent the most clinically challenging group. The label does not address partial responders explicitly. A reasonable approach, documented in clinical practice but without RCT support, is to continue the full 100 mg course through week 12 while optimizing contributing behavioral factors, then reassess before switching to bremelanotide or pursuing testosterone therapy.